PD-1/PD-L1抑制剂相关心肌炎的研究进展

Progress in the treatment of PD-1/PD-L1 inhibitor-associated myocarditis

随着现代医学的迅速发展,肿瘤免疫治疗已经成为肿瘤治疗领域里极为重要的治疗手段。其中抗程序细胞死亡蛋白1(PD-1)及其配体(PD-L1)免疫检查点抑制剂已被美国食品药品监督管理局批准用于恶性黑色素瘤、转移性鳞状非小细胞肺癌、晚期肾癌、头颈鳞状细胞癌、尿路上皮癌等肿瘤的治疗。随着PD-1/PD-L1抑制剂在国内外的广泛应用,许多肿瘤患者的生存率显著提升,但也出现了一系列的免疫相关不良反应(irAEs),其中免疫抑制剂相关心肌炎是最凶险的一种。本文就PD-1/PD-L1抑制剂相关心肌炎的研究进展进行综述。

With the rapid development of modern medicine,immunotherapy of tumors has become an important method in tumor therapy.Among them,programmed death^(-1)(PD-1)and programmed death-ligand 1(PD-L1)immune checkpoint inhibitors have been approved by the US Food and Drugs Administration in the treatment of malignant melanoma,metastatic squamous non-small cell lung cancer,advanced kidney cancer,head and neck squamous cell carcinoma,urothelium carcinoma,etc.With the wide application of PD-1/PD-L1 inhibitors at home and abroad,many immune-related adverse events have occurred along with the significant improvement in the survival rate of tumor patients,among which immune checkpoint inhibitor-related myocarditis is most dangerous.This paper reviewed the research progress in PD-1/PD-L1 inhibitor associated myocarditis.